Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
N Engl J Med ; 369(5): 417-27, 2013 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-23902481

RESUMEN

BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months. The primary outcome measure was complete remission of disease by 6 months, with the remission maintained through 18 months. RESULTS: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the comparison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P=0.01) and at 12 months (P=0.009) but not at 18 months (P=0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. CONCLUSIONS: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)


Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Azatioprina/uso terapéutico , Ciclofosfamida/uso terapéutico , Factores Inmunológicos/administración & dosificación , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Azatioprina/efectos adversos , Linfocitos B , Ciclofosfamida/efectos adversos , Método Doble Ciego , Esquema de Medicación , Quimioterapia Combinada , Glucocorticoides/uso terapéutico , Humanos , Factores Inmunológicos/efectos adversos , Factores Inmunológicos/uso terapéutico , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Estimación de Kaplan-Meier , Recurrencia , Inducción de Remisión , Rituximab
2.
N Engl J Med ; 363(3): 221-32, 2010 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-20647199

RESUMEN

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS: We conducted a multicenter, randomized, double-blind, double-dummy, noninferiority trial of rituximab (375 mg per square meter of body-surface area per week for 4 weeks) as compared with cyclophosphamide (2 mg per kilogram of body weight per day) for remission induction. Glucocorticoids were tapered off; the primary end point was remission of disease without the use of prednisone at 6 months. RESULTS: Nine centers enrolled 197 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis. Baseline disease activity, organ involvement, and the proportion of patients with relapsing disease were similar in the two treatment groups. Sixty-three patients in the rituximab group (64%) reached the primary end point, as compared with 52 patients in the control group (53%), a result that met the criterion for noninferiority (P<0.001). The rituximab-based regimen was more efficacious than the cyclophosphamide-based regimen for inducing remission of relapsing disease; 34 of 51 patients in the rituximab group (67%) as compared with 21 of 50 patients in the control group (42%) reached the primary end point (P=0.01). Rituximab was also as effective as cyclophosphamide in the treatment of patients with major renal disease or alveolar hemorrhage. There were no significant differences between the treatment groups with respect to rates of adverse events. CONCLUSIONS: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Ciclofosfamida/uso terapéutico , Granulomatosis con Poliangitis/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Poliangitis Microscópica/tratamiento farmacológico , Administración Oral , Anciano , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales de Origen Murino , Linfocitos B/efectos de los fármacos , Ciclofosfamida/efectos adversos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Humanos , Inmunosupresores/efectos adversos , Análisis de Intención de Tratar , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Neoplasias/epidemiología , Prednisona/uso terapéutico , Calidad de Vida , Inducción de Remisión , Rituximab
3.
J Infus Nurs ; 29(5): 272-82, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17035889

RESUMEN

Vasculitis is a heterogeneous group of uncommon, complex rheumatologic diseases. These diseases are known for their high mortality and morbidity rates due to the underlying disorders themselves, as well as complications of their conventional treatments. Oral and intravenous glucocorticosteroids and other immunosuppressive agents such as cyclophosphamide, methotrexate, and azathioprine are used to manage these diseases. These therapies are effective, but they have a global impact (often negative) on patients' immune systems and cause a number of nonimmunologic toxicities. They also are ineffective in inducing long-term remissions. Novel biologic infusion agents such as rituximab and infliximab are being prescribed off-label for some patients with vasculitis who have failed to respond to conventional therapy or because there are contraindications to standard-of-care treatments. This article provides an orientation to vasculitis, its standard of care, infusion biologics under investigation in these diseases, and the nursing implications for infusion professionals.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoterapia/métodos , Vasculitis/terapia , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales de Origen Murino , Arteritis de Células Gigantes/inmunología , Arteritis de Células Gigantes/enfermería , Arteritis de Células Gigantes/terapia , Granulomatosis con Poliangitis/inmunología , Granulomatosis con Poliangitis/enfermería , Granulomatosis con Poliangitis/terapia , Humanos , Infliximab , Infusiones Intravenosas/enfermería , Rituximab , Vasculitis/inmunología , Vasculitis/enfermería
4.
Arthritis Rheum ; 54(5): 1608-18, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16646004

RESUMEN

OBJECTIVE: Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. METHODS: One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. RESULTS: All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment. CONCLUSION: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.


Asunto(s)
Granulomatosis con Poliangitis/tratamiento farmacológico , Inmunoglobulina G/efectos adversos , Neoplasias/inducido químicamente , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Anciano , Ensayos Clínicos como Asunto , Etanercept , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Receptores del Factor de Necrosis Tumoral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...